Vaxxinity’s Cholesterol Vaccine Candidate Successfully Lowers LDL-C: Preclinical Data Published
Vaxxinity, Inc. (VAXX)
Company Research
Source: GlobeNewswire
Preclinical data published in the Journal of Lipid Research indicate VXX-401 is well-tolerated, with no safety signals observed, and robustly reduces LDL-C in cynomolgus monkeys. A Phase 1 trial of VXX-401 is ongoing, with topline results expected mid-2024. CAPE CANAVERAL, Fla., Feb. 15, 2024 (GLOBE NEWSWIRE) -- Vaxxinity, Inc. (Nasdaq: VAXX), a U.S. company pioneering the development of a new class of medicines, today announced the publication of data from multiple non-human primate studies demonstrating that VXX-401 reproducibly lowers low-density lipoprotein cholesterol (LDL-C) in non-human primates. The results, which support the continued clinical development of VXX-401 as a candidate for the treatment of hypercholesterolemia and prevention of atherosclerotic cardiovascular disease, were published in the Journal of Lipid Research (Volume 65, Issue 2, 100497, February 2024). VXX-401 is a synthetic peptide vaccine designed to stimulate the immune system to produce antibodies t
Show less
Read more
Impact Snapshot
Event Time:
VAXX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VAXX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VAXX alerts
High impacting Vaxxinity, Inc. news events
Weekly update
A roundup of the hottest topics
VAXX
News
- Vaxxinity Issues Shareholder Letter [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Issues Shareholder LetterGlobeNewswire
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common Stock [Yahoo! Finance]Yahoo! Finance
- Vaxxinity Announces Intention to Voluntarily Delist and Deregister its Class A Common StockGlobeNewswire
- Vaxxinity to Present Clinical Data at the Annual Academy of Neurology 2024 Annual Meeting [Yahoo! Finance]Yahoo! Finance
VAXX
Earnings
- 3/27/24 - Beat
VAXX
Sec Filings
- 5/3/24 - Form EFFECT
- 4/30/24 - Form S-8
- 4/30/24 - Form S-8
- VAXX's page on the SEC website